Ashraf Sajda, Qaiser Hina, Tariq Sumayya, Khalid Asaad, Makeen Hafiz A, Alhazmi Hassan A, Ul-Haq Zaheer
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75210, Pakistan.
Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box: 114, Jazan, Saudi Arabia.
Curr Res Struct Biol. 2023 Nov 27;6:100114. doi: 10.1016/j.crstbi.2023.100114. eCollection 2023.
Human serum albumin (HSA) is a multi-domain macromolecule with diverse ligand binding capability because of its ability to allow allosteric modulation despite being a monomeric protein. Physiologically, HSA act as the primary carrier for various exogenous and endogenous compounds and fatty acids, and alter the pharmacokinetic properties of several drugs. It has antioxidant properties and is utilized therapeutically to improve the drug delivery of pharmacological agents for the treatment of several disorders. The flexibility of albumin in holding various types of drugs coupled with a variety of modifications makes this protein a versatile drug carrier with incalculable potential in therapeutics. This review provides a brief outline of the different structural properties of HSA, and its various binding sites, moreover, an overview of the genetic, biomedical, and allosteric modulation of drugs and drug delivery aspects of HSA is also included, which may be helpful in guiding advanced clinical applications and further research on the therapeutic potential of this extraordinary protein.
人血清白蛋白(HSA)是一种多结构域大分子,尽管它是单体蛋白,但由于其具有变构调节能力,因此具有多种配体结合能力。在生理上,HSA作为各种外源性和内源性化合物及脂肪酸的主要载体,并改变几种药物的药代动力学性质。它具有抗氧化特性,在治疗上可用于改善治疗多种疾病的药物的药物递送。白蛋白结合各种类型药物的灵活性以及多种修饰使这种蛋白质成为一种多功能药物载体,在治疗学上具有不可估量的潜力。本综述简要概述了HSA的不同结构特性及其各种结合位点,此外,还包括对HSA的遗传、生物医学以及药物的变构调节和药物递送方面的概述,这可能有助于指导先进的临床应用以及对这种非凡蛋白质的治疗潜力进行进一步研究。
Curr Med Chem. 2020
Mini Rev Med Chem. 2006-4
IUBMB Life. 2005-12
Mol Aspects Med. 2011-12-30
Biochim Biophys Acta. 2013-12
Int J Biol Macromol. 2018-11-12
J Biomol Struct Dyn. 2024-2-12
ACS Omega. 2025-6-27
Front Endocrinol (Lausanne). 2025-7-2
J Proteome Res. 2025-7-4
Pharmaceuticals (Basel). 2025-4-16
Blood. 2024-9-19
Front Chem. 2022-7-11
Rev Neurosci. 2022-10-26
Int J Biol Macromol. 2021-9-30
Curr Gastroenterol Rep. 2021-7-2
J Nanobiotechnology. 2021-5-29
J Pharm Sci. 2021-9